The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-10-deficient mice develop chronic enterocolitis
Kühn, R., Löhler, J., Rennick, D., Rajewsky, K., & Müller, W. (1993) · Cell · doi:10.1016/0092-8674(93)80068-p · Cited by 4,274
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Measurement of Cutaneous Inflammation: Estimation of Neutrophil Content with an Enzyme Marker
Bradley, P. P., Priebat, D. A., Christensen, R. D., & Rothstein, G. (1982) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12506462 · Cited by 3,626
Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y., & Nakaya, R. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90290-h · Cited by 2,401
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
The Pathophysiology Of Tumor Necrosis Factors
VASSALLI, P. (1992) · Annual Review of Immunology · doi:10.1146/annurev.immunol.10.1.411 · Cited by 1,920
The immunological and genetic basis of inflammatory bowel disease
Bouma, G., & Strober, W. (2003) · Nature Reviews Immunology · doi:10.1038/nri1132 · Cited by 1,767
Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Cited by
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
Salminen, S., Collado, M. C., Endo, A., Hill, C., Lebeer, S., Quigley, E. M. M., Sanders, M. E., Shamir, R., Swann, J. R., Szajewska, H., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00440-6 · Cited by 2,488
Swanson, K. S., Gibson, G. R., Hutkins, R., Reimer, R. A., Reid, G., Verbeke, K., Scott, K. P., Holscher, H. D., Azad, M. B., Delzenne, N. M., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0344-2 · Cited by 2,196
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Engineered living biomaterials
Rodrigo-Navarro, A., Sankaran, S., Dalby, M. J., del Campo, A., & Salmeron-Sanchez, M. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00350-8 · Cited by 494
The intestinal barrier: a pivotal role in health, inflammation, and cancer
Neurath, M. F., Artis, D., & Becker, C. (2025) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00390-x · Cited by 487
Nanobodies as therapeutics: big opportunities for small antibodies
Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 468
Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut
Praveschotinunt, P., Duraj-Thatte, A. M., Gelfat, I., Bahl, F., Chou, D. B., & Joshi, N. S. (2019) · Nature Communications · doi:10.1038/s41467-019-13336-6 · Cited by 463
Engineering bacteria for diagnostic and therapeutic applications
Riglar, D. T., & Silver, P. A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.172 · Cited by 460
Microbiota and metabolic diseases
Pascale, A., Marchesi, N., Marelli, C., Coppola, A., Luzi, L., Govoni, S., Giustina, A., & Gazzaruso, C. (2018) · Endocrine · doi:10.1007/s12020-018-1605-5 · Cited by 423
Engineering living therapeutics with synthetic biology
Cubillos-Ruiz, A., Guo, T., Sokolovska, A., Miller, P. F., Collins, J. J., Lu, T. K., & Lora, J. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00285-3 · Cited by 356
Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts
Moroz, E., Matoori, S., & Leroux, J.-C. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.010 · Cited by 336
Inflammation in Renal Diseases: New and Old Players
Andrade-Oliveira, V., Foresto-Neto, O., Watanabe, I. K. M., Zatz, R., & Câmara, N. O. S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01192 · Cited by 330
Microbiome therapeutics — Advances and challenges
Mimee, M., Citorik, R. J., & Lu, T. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.032 · Cited by 317
Plichta, D. R., Graham, D. B., Subramanian, S., & Xavier, R. J. (2019) · Cell · doi:10.1016/j.cell.2019.07.045 · Cited by 310
New targets for mucosal healing and therapy in inflammatory bowel diseases
Neurath, M. F. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.73 · Cited by 309
Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies
Kim, D. H., & Cheon, J. H. (2017) · Immune Network · doi:10.4110/in.2017.17.1.25 · Cited by 295
Probiotics: Properties, Examples, and Specific Applications
Behnsen, J., Deriu, E., Sassone-Corsi, M., & Raffatellu, M. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a010074 · Cited by 293
Drug delivery strategies in the therapy of inflammatory bowel disease
Lautenschläger, C., Schmidt, C., Fischer, D., & Stallmach, A. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.10.001 · Cited by 291
Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa
Collnot, E.-M., Ali, H., & Lehr, C.-M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.028 · Cited by 254
Immunomodulation by commensal and probiotic bacteria
Forsythe, P., & Bienenstock, J. (2010) · Immunological Investigations · doi:10.3109/08820131003667978 · Cited by 189
Developments and Challenges for mAb-Based Therapeutics
Goswami, S., Wang, W., Arakawa, T., & Ohtake, S. (2013) · Antibodies · doi:10.3390/antib2030452 · Cited by 144
“These functionally active dAbs and nanobodies can be reformatted into a linked dAb or CH1/CL dAb, or be attached to VH and/or VL chains, or the CH3 of a regular antibody to make a bispecific or multispecific molecule [287].”
BackgroundCarlucci, C., Petrof, E. O., & Allen-Vercoe, E. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.09.029 · Cited by 77
Role of the intestinal microbiota in the immunomodulation of influenza virus infection
Chen, C.-J., Wu, G.-H., Kuo, R.-L., & Shih, S.-R. (2017) · Microbes and Infection · doi:10.1016/j.micinf.2017.09.002 · Cited by 67
Genetically Engineered Microorganisms and Their Impact on Human Health
Mahdizade Ari, M., Dadgar, L., Elahi, Z., Ghanavati, R., & Taheri, B. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/6638269 · Cited by 67
Zahedifard, Z., Mahmoodi, S., & Ghasemian, A. (2025) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2738 · Cited by 12
Metadata
- Authors
- Vandenbroucke, K., de Haard, H., Beirnaert, E., Dreier, T., Lauwereys, M., Huyck, L., Van Huysse, J., Demetter, P., Steidler, L., Remaut, E., Cuvelier, C., & Rottiers, P.
- Venue
- Mucosal Immunology
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 3
- Issue
- 1
- Pages
- 49-56
- ISSN
- 1933-0219 (ISSN-L)
- OpenAlex
- W2083323027
- Cited by
- 289
- References
- 44
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.